4564.T stock: OncoTherapy Science JPY 21.00 on JPX most active, watch 30 Jan
The most active JPX ticker today is 4564.T stock as OncoTherapy Science, Inc. trades at JPY 21.00 with intraday range JPY 20.00–21.00 and volume at 24,145,600.00 shares. Market attention is concentrated ahead of an earnings announcement scheduled for 30 January 2026 and heavy intraday turnover versus the 50-day average of 21.78 JPY. We summarise why liquidity, valuation, and upcoming clinical milestones are driving trades in Japan.
Intraday movers: 4564.T stock volume and price action
OncoTherapy Science (4564.T) is showing heavy trading on JPX with 24,145,600.00 shares traded versus an average of 60,934,308.00, a relative volume of 0.37. The stock opened at JPY 20.00 and is trading at JPY 21.00, holding near the day high. The intraday move connects to renewed investor focus on the company’s clinical pipeline and the pending earnings release on 30 January 2026. Yahoo Finance coverage notes the share uptick among biotech peers.
Valuation and financials: 4564.T stock key metrics
OncoTherapy Science trades at market cap JPY 7,111,807,773.00 with 338,657,513.00 shares outstanding and book value per share JPY 5.17. Trailing EPS is -2.83 and PE is -7.42, reflecting negative earnings. Key ratios show price-to-sales 7.43 and price-to-book 4.06, and a strong current ratio of 8.63, indicating ample short-term liquidity. These metrics explain the mixed analyst view and elevated volatility for a small-cap biotechnology name on the JPX.
Technical view: 4564.T stock indicators
Momentum is neutral: RSI 49.91 and MACD histogram 0.10 suggest a balanced intraday bias, while ATR 1.51 points to moderate volatility around the JPY 21.00 price. Bollinger Bands sit JPY 19.42 to JPY 21.98, supporting the stock’s current position near the upper band. Traders watching intraday setups should note ADX 10.20 indicating no strong trend and OBV at -423,870,300.00 reflecting longer-term outflows.
Meyka grade and forecast: 4564.T stock rating
Meyka AI rates 4564.T with a score out of 100: the model gives a 70.43 score, grade B+ and a suggestion to BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly JPY 21.15, yearly JPY 16.73 and three-year JPY 11.87, implying a +0.71% one-month upside and a -20.33% one-year downside versus current JPY 21.00; forecasts are model-based projections and not guarantees.
Catalysts and risks for 4564.T stock outlook
The primary catalyst is the earnings and clinical updates window on 30 January 2026 and ongoing Phase III data for S-588410. Upside depends on positive trial data or licensing deals; downside stems from negative EPS trends (EPS -2.83) and thin analyst coverage. OncoTherapy’s R&D expense ratio at 53.91% of revenue underlines cash burn risk despite current cash per share JPY 5.26 and a conservative debt-to-equity 0.01.
Trading note: liquidity, sector context and strategy for 4564.T stock
As a most-active small-cap biotech on JPX, 4564.T stock shows episodic liquidity with average volume 60,934,308.00 but intraday spikes that can widen spreads. The Healthcare sector on Japan exchanges is up ~12.50% YTD, so relative sector strength matters for positioning. Short-term traders should focus on event-driven entries and strict risk limits; longer-term investors must weigh pipeline probability and cash runway.
Final Thoughts
Key takeaways for 4564.T stock: OncoTherapy Science trades at JPY 21.00 on the JPX with a heavy intraday volume spike of 24,145,600.00 shares and an upcoming earnings and clinical update on 30 January 2026 that is central to the near-term outlook. Valuation remains stretched with price-to-sales 7.43 and negative EPS -2.83, while balance-sheet metrics such as current ratio 8.63 provide short-term stability. Meyka AI’s forecast model projects a one-year target of JPY 16.73, implying a -20.33% downside from today’s price; monthly projection is JPY 21.15, near current levels. Traders should treat today’s activity as event-driven liquidity rather than a durable trend and prepare for binary clinical risk. For ongoing updates and intraday feeds see our Meyka AI-powered market analysis and public filings; monitor Reuters and Yahoo Finance for headlines and company disclosures Reuters profile Yahoo summary. Forecasts are model-based projections and not guarantees.
FAQs
4564.T stock is trading at **JPY 21.00** on the JPX intraday session with volume **24,145,600.00** shares and an intraday range **JPY 20.00–21.00**; liquidity is high vs short-term averages.
Key metrics: market cap **JPY 7,111,807,773.00**, EPS **-2.83**, PE **-7.42**, price-to-sales **7.43**, and price-to-book **4.06**, reflecting negative earnings and biotech development risk.
Meyka AI rates 4564.T with a score of **70.43/100**, grade **B+** (BUY). Meyka AI’s forecast model projects yearly **JPY 16.73**, implying **-20.33%** vs current price; forecasts are projections, not guarantees.
Watch the earnings and clinical updates scheduled for 30 January 2026, Phase III progress for S-588410, and any licensing announcements; these events drive short-term moves and liquidity.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
